[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345333-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345333-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","circulating-tumor-cells-emerging-frontiers-in-cancer-technology","Circulating Tumor Cells - Emerging Frontiers in Cancer Technology","","Circulating tumor cells (CTCs) are rare cells shedding from a primary tumor into the bloodstream, implicated in metastasis, immune evasion, and recurrence across cancers. Key detection-relevant biomarkers include EpCAM, HER2, PD-L1, CD45, and other cancer-specific molecules, with discussion of their limitations as single markers. The review synthesizes CTC characteristics, isolation and detection technologies, and emerging nanocarrier-based therapeutic approaches, weighing current physical and research barriers while highlighting integrative strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/circulating-tumor-cells-emerging-frontiers-in-cancer-technology/345333/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/circulating-tumor-cells-emerging-frontiers-in-cancer-technology/345333.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are circulating tumor cells (CTCs) and why are they important?","Question",{"text":63,"@type":64},"CTCs are tumor cells that enter the vasculature from a primary tumor and can contribute to metastasis. They are also linked to immune evasion and recurrence, making them relevant to prognosis and therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which biomarkers are commonly discussed for CTC detection?",{"text":68,"@type":64},"The review highlights EpCAM, HER2, PD-L1, CD45, and other cancer-specific biomolecules as detection-associated markers.",{"name":70,"@type":61,"acceptedAnswer":71},"How do emerging technologies and treatments target or use CTCs?",{"text":72,"@type":64},"The review discusses recent isolation and detection technologies, including approaches based on cell-specific biomarker inclusion/exclusion, and emerging therapies that integrate CTCs such as nanocarrier-mediated drug delivery.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345333,1790735300,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Expert Reviews in Molecular Medicine  \n[www.cambridge.org/erm](www.cambridge.org/erm)  \nReview  \nCite this article: Agarwal P, Raman R, Bhagwat M, Agarwal P and Kumar P (2026) . Circulating Tumor Cells: Emerging Frontiers in Cancer Technology. Expert Reviews in Molecular Medicine, 28, e10, 1–22  \n[https://doi.org/10.1017/erm.2026.10039](https://doi.org/10.1017/erm.2026.10039)  \nReceived: 03 September 2025  \nRevised: 17 January 2026  \nAccepted: 13 February 2026  \nKeywords:  \nbiomarkers; circulating tumor cells; immune surveillance; magnetic immunocapture; nano targeting; stemness  \nCorresponding author:  \nPraveen Kumar;  \nEmail: [kumar.praveen@manipal.edu](kumar.praveen@manipal.edu)  \n[P.A. and R.R. equal contribution.](P.A. and R.R. equal contribution.)  \n© The Author(s), 2026 . Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence ([http://](http://)[ ](http://)[creativecommons.org/licenses/by/4.0](creativecommons.org/licenses/by/4.0)), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.  \nCirculating Tumor Cells: Emerging Frontiers in Cancer Technology  \nParth Agarwal1 , Rachana Raman1 , Manasa Bhagwat1, Prasoon Agarwal2  and Praveen Kumar1   \n1Manipal Institute of Technology, Manipal Academy of Higher Education, Manipal, India and 2National Bioinformatics Infrastructure Sweden (NBIS), SciLifeLab, Division of Occupational and Environmental Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden  \nAbstract  \nBackground: Circulating tumour cells (CTCs) are unique cells that originate from the main tumor site. They circulate in the bloodstream, and are implicated in metastasis, immune evasion and recurrence in various cancers. Associated biomarkers of importance for CTC detection include epithelial cell adhesion molecule (EpCAM), human epidermal growth factor receptor 2 (HER2), programmed death ligand-1 (PD-L1), cluster of differentiation 45 (CD45) and other cancer-specific biomolecules. Their roles as standalone biomarkers, have been thoroughly examined in CTC detection, isolation and targeting.  \nMethods: This review collates key findings on CTC characteristics and biomarker identification. The most recent CTC isolation and detection technologies are discussed, along with individual approaches based on inclusion and exclusion of cell-specific biomarkers. Emerging treatments integrating CTCs, including nanocarrier-mediated drug delivery, have been analyzed. We have discussed both the physical and research barriers in the current landscape.  \nResults: Recent advances have determined that such biomarkers are more reliable when associated with secondary biomarkers, due to concerns regarding immune evasion and low sensitivity. The identification of these molecules has fast-tracked the development of several groundbreaking technologies.  \nConclusion: The prognostic and predictive role ofCTCs in various cancers revealed promising results. The development of integrative therapeutics can enhance patient survival and quality of life. These advancements depend on addressing key issues, such as molecular characterization and low abundance of CTCs.  \nIntroduction  \nCirculating tumor cells (CTCs) are tumor cells that eroded into the vasculature from the primary tumor and have the capacity to form new cancers away from the original site (Ref. 1) . Thomas Ashworth first identified them in 1869, and he described them as having significant metastatic potential (Ref. 2) . As our understanding of cancer progressed in the later 20th century, the divergent roles of cells within a tumor were also extensively studied. Tumours may be solid, as in the case of carcinomas, lymphomas and sarcomas, or ‘liquid’, as in the case of leukemias or myelomas (Ref. 3). Thus, tumor pathology has lent itself to be a core discipline in understanding the true nature of cancer, and thereby addressin","cbCaipxaq7UbByzY","https://ap.wps.com/l/cbCaipxaq7UbByzY","pdf",1015099,22,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What are circulating tumor cells (CTCs) and why are they important?\",\"answer\":\"CTCs are tumor cells that enter the vasculature from a primary tumor and can contribute to metastasis. They are also linked to immune evasion and recurrence, making them relevant to prognosis and therapy.\"},{\"question\":\"Which biomarkers are commonly discussed for CTC detection?\",\"answer\":\"The review highlights EpCAM, HER2, PD-L1, CD45, and other cancer-specific biomolecules as detection-associated markers.\"},{\"question\":\"How do emerging technologies and treatments target or use CTCs?\",\"answer\":\"The review discusses recent isolation and detection technologies, including approaches based on cell-specific biomarker inclusion/exclusion, and emerging therapies that integrate CTCs such as nanocarrier-mediated drug delivery.\"}]","Circulating Tumor Cells - Emerging Frontiers in Cancer Technology | PDF",1790057314,55,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/830e1cee9a99b2a9f62876acec5b2ebe.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2395bae793a30c62e644e6642201536.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b65bda576ed936efcbfee81d39cf68c3.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a35ad375231a0133a22aef7170b47241.webp",980,1306]